Antirheumatic treatment, disease activity and risk of Staphylococcus aureus bacteraemia in rheumatoid arthritis: a nationwide nested case-control study.
Sabine Sparre DieperinkFrank MehnertMette NørgaardLouise Bruun OestergaardThomas BenfieldAndreas PetersenChristian Torp-PedersenBente GlintborgMerete Lund HetlandPublished in: RMD open (2022)
We identified a dose-dependent increased risk of SAB in patients with RA currently using oral glucocorticoids. Daily use of >7.5 mg appeared to be a clinically relevant risk factor, whereas the absolute risk was low for bDMARDs. No clear impact of disease activity was found.
Keyphrases
- disease activity
- rheumatoid arthritis
- rheumatoid arthritis patients
- ankylosing spondylitis
- systemic lupus erythematosus
- staphylococcus aureus
- juvenile idiopathic arthritis
- risk factors
- interstitial lung disease
- physical activity
- cross sectional
- biofilm formation
- escherichia coli
- pseudomonas aeruginosa
- case control
- smoking cessation